3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Dexamethasone
17
Lenalidomide
15
Bortezomib
12
Cyclophosphamide
7
fludarabine
6
carfilzomib
6
Melphalan
6
daratumumab
5
Calcium Dobesilate
5
pomalidomide
3
gamma-Globulins
3
fludarabine phosphate
3
belantamab mafodotin
3
Whole-Body Irradiation
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Tacrolimus
3
Mycophenolic Acid
3
isatuximab
2
elotuzumab
2
Sirolimus
2
Prednisone
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Ciprofloxacin
2
Amoxicillin-Potassium Clavulanate Combination
2
venetoclax
1
thymoglobulin
1
siltuximab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Transplantation, Autologous
×
1 year
×
Clear all
NCT02244125
2025-11-24
PCD
Institut Curie
Phase 2
Completed
100 enrolled